Dendritic cells engineered to express defined Allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells

Scandinavian Journal of Immunology

Volumn 69, Issue 4, 2009, Pages 319-328

  Stronen, E ^b   Abrahamsen, I W ^b   Gaudernack, G ^b   Walchli S ^b   Munthe, E ^b   Buus, S ^c   Johansen, F E ^b   Lund Johansen, F ^b   Olweus, J ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD19 ANTIGEN; CD33 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN; LEUKEMIA ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MELAN A; MESSENGER RNA; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BIOENGINEERING; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL KILLING; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETIC TRANSFECTION; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR CELL;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY; ISOANTIGENS; LYMPHOCYTE ACTIVATION; PEPTIDES; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 61849182423     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02223.x     Document Type: Article

References (33)

1. Gao L, Downs AM, Stauss HJ. Immunotherapy with CTL restricted by nonself MHC. Methods Mol Med 2005 109 : 215 28.
2. Madrigal AJ, Rusakiewicz S, Dodi AI, Rees R. Immunotherapy with alloreactive T-cells? Hematol J 2004 5 (Suppl. 3 S91 5.
3. Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nat Rev Immunol 2007 7 : 942 53.
4. Pittet MJ, Gati A, Le Gal FA et al. Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J Immunol 2006 176 : 2330 6.
5. Schuster IG, Busch DH, Eppinger E et al. Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. Blood 2007 110 : 2931 9.
6. Stanislawski T, Voss RH, Lotz C et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001 2 : 962 70.
7. Amrolia PJ, Reid SD, Gao L et al. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 2003 101 : 1007 14.
8. Dutoit V, Guillaume P, Romero P, Cerottini JC, Valmori D. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition. Cancer Immun 2002 2 : 7.
9. Saeboe-Larssen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 2002 259 : 191 203.
10. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995 42 : 455 500.
11. Openshaw P, Murphy EE, Hosken NA et al. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 1995 182 : 1357 67.
12. Betts MR, Brenchley JM, Price DA et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003 281 : 65 78.
13. Betts MR, Nason MC, West SM et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006 107 : 4781 9.
14. Barnstable CJ, Bodmer WF, Brown G et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978 14 : 9 20.
15. Valmori D, Fonteneau JF, Lizana CM et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998 160 : 1750 8.
16. Genevee C, Diu A, Nierat J et al. An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol 1992 22 : 1261 9.
17. Pittet MJ, Valmori D, Dunbar PR et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999 190 : 705 15.
18. Trautmann L, Labarriere N, Jotereau F et al. Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol 2002 32 : 3181 90.
19. Mantovani S, Palermo B, Garbelli S et al. Dominant TCR-alpha requirements for a self antigen recognition in humans. J Immunol 2002 169 : 6253 60.
20. Moss PA, Rosenberg WM, Bell JI. The human T cell receptor in health and disease. Annu Rev Immunol 1992 10 : 71 96.
21. Buus S, Lauemoller SL, Worning P et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. Tissue Antigens 2003 62 : 378 84.
22. DeMars R, Chang CC, Shaw S, Reitnauer PJ, Sondel PM. Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum Immunol 1984 11 : 77 97.
23. Townsend A, Ohlen C, Foster L, Bastin J, Ljunggren HG, Karre K. A mutant cell in which association of class I heavy and light chains is induced by viral peptides. Cold Spring Harb Symp Quant Biol 1989 54 (Pt 1 299 308.
24. Alexander J, Payne JA, Murray R, Frelinger JA, Cresswell P. Differential transport requirements of HLA and H-2 class I glycoproteins. Immunogenetics 1989 29 : 380 8.
25. Savage P, Gao L, Vento K et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 2004 103 : 4613 5.
26. Gao L, Bellantuono I, Elsasser A et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000 95 : 2198 203.
27. Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 2008 34 : 49 60.
28. Felix NJ, Suri A, Walters JJ, Horvath S, Gross ML, Allen PM. I-Ep-bound self-peptides: identification, characterization, and role in alloreactivity. J Immunol 2006 176 : 1062 71.
29. Housset D, Malissen B. What do TCR-pMHC crystal structures teach us about MHC restriction and alloreactivity? Trends Immunol 2003 24 : 429 37.
30. Mazza C, Auphan-Anezin N, Gregoire C et al. How much can a T-cell antigen receptor adapt to structurally distinct antigenic peptides? EMBO J 2007 26 : 1972 83.
31. Reiser JB, Darnault C, Gregoire C et al. CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Nat Immunol 2003 4 : 241 7.
32. Felix NJ, Donermeyer DL, Horvath S et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 2007 8 : 388 97.
33. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006 314 : 126 9.